Reference

Angiopoietin antagonists are a class of drugs that target the angiopoietin/Tie2 signaling pathway, which plays a crucial role in angiogenesis and vascular stability. These antagonists are often used in research and therapeutic contexts to modulate blood vessel formation and function. Some of the known angiopoietin antagonists include:

1. Trebananib (AMG 386): This is a peptide-Fc fusion protein that acts as an angiopoietin antagonist by inhibiting the interaction between angiopoietins (Ang1 and Ang2) and the Tie2 receptor. It has been investigated for its potential in treating various cancers by inhibiting tumor angiogenesis.

2. REGN910 (also known as Nesvacumab): This is a monoclonal antibody that specifically targets Ang2, preventing it from binding to the Tie2 receptor. By blocking Ang2, it helps to stabilize blood vessels and reduce pathological angiogenesis.

3. CVX-060: This is another Ang2-specific antibody that acts as an antagonist, inhibiting the binding of Ang2 to the Tie2 receptor, thereby modulating angiogenesis.

These agents are primarily used in the context of cancer therapy and other diseases where abnormal angiogenesis is a factor. They work by disrupting the signaling pathways that promote the growth of new blood vessels, which is a critical process in tumor development and progression.